30 June 2016

Sinclair IS Pharma cuts loss 

Robert Tyerman

Recently-merged Sinclair IS Pharma (SPH.L) has cut annual losses 31 per cent to £11.7 million and launched an Asia-Pacific marketing drive. The AIM-quoted company, which specialises in oral health, dermatology and wound care, increased turnover 19 per cent to nearly £33 million in the year to June.

Steered by entrepreneurial chief executive Chris Spooner, Sinclair, whose losses before exceptional items rose 14.5 per cent to £5.8 million, achieved several product launches last year. The company introduced its Autopiclair eczema and dermatitis cream into France, a market which returned to growth last year with a 21 per cent turnover gain to £12.5 million, and took its Kelo-cote scar reduction formulation into several European markets.

Outgoing chairman John Gregory says the merger of Sinclair Pharma with IS Pharma should lead to annual cost savings of £1 million and has already started to pay off more positively, as with a marketing agreement for the company's Episil treatment for oral mucositis pain. Grahame Cook, already a Sinclair director, will now chair the company, which has already launched two dermatology products in seven Asia-Pacific countries under its partnership with Singapore-based Invida Holdings, a leader in commercialising bio-pharmaceutical and healthcare products in the region.

Sinclair, which ended the financial year with £5 million cash, now has a 'bio-film busting' mouthwash for sale in the USA under the PerioShield banner through an agreement with Sunstar Americas and has several new products in the pipeline. Highlighted by Growth Company Investor at 28p last autumn, Sinclair shares have eased to 24p, valuing the company at £93.3 million, but could still outperform some sector peers over the medium term.

Tags: AIM market, Asia-Pacifuyc, Autopiclair, Chris Spooner, Dermatology, Wound care

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Avingtrans returns cash and remains a Buy

Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.

Omega investing in growth

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials 

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

Wincanton keeps on trucking

Wincanton CEO Adrian Colman feels his company is now back on an even keel after a period of fire-fighting. Debt has been brought under control, the pension deficit is being addressed, and onerous leases and contracts have been dealt with. A return to the dividend list illustrates these positive changes and the fact that management can now fully focus on growing the business.

More News